CVM
CEL-SCI Corporation
Price Chart
Latest Quote
$1.04
-0.06 (-5.45%)
Current Price
| Previous Close | $1.10 |
| Open | $1.13 |
| Day High | $1.17 |
| Day Low | $1.02 |
| Volume | 522,945 |
Stock Information
| Shares Outstanding | 17.48M |
| Total Debt | $8.51M |
| Cash Equivalents | $1.90M |
| Net Income | $-22.70M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $18.18M |
| EPS (TTM) | $-2.15 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $15.45M |
| Income | $-22.70M |
| Book/sh | $0.81 |
| Cash/sh | $0.11 |
Financial Ratios
| Quick Ratio | 0.40 |
| Current Ratio | 0.60 |
| Debt/Eq | 123.82 |
Returns & Margins
| ROA | -70.28% |
| ROE | -305.27% |
Ownership
| Insider Ownership | 4.53% |
| Institutional Ownership | 4.45% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.13 |
| PEG | 1.12 |
| P/B | 1.29 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.31 |
| SMA50 | $2.18 |
| SMA200 | $5.37 |
| RSI | 19.51 |
| ATR | 0.1214 |
| Shares Float | 8.17M |
| Short Float | 1.60% |
| Short Ratio | 0.27 |
| Volatility | 0.60 |
| Rel Volume | 1.49 |
Performance History
| Week | -6.31% |
| Month | -34.59% |
| Quarter | -71.58% |
| 6 Months | -82.37% |
| YTD | -79.81% |
| Year | -55.17% |
| 3 Years | -98.60% |
| 5 Years | -99.84% |
| 10 Years | -99.70% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.04 | 524,300 |
| 2026-06-17 | $1.10 | 684,500 |
| 2026-06-16 | $1.01 | 480,700 |
| 2026-06-15 | $1.01 | 680,600 |
| 2026-06-12 | $1.08 | 836,200 |
| 2026-06-11 | $1.11 | 478,100 |
| 2026-06-10 | $1.18 | 357,200 |
| 2026-06-09 | $1.30 | 239,700 |
| 2026-06-08 | $1.38 | 160,600 |
| 2026-06-05 | $1.37 | 336,900 |
| 2026-06-04 | $1.53 | 146,800 |
| 2026-06-03 | $1.48 | 139,000 |
| 2026-06-02 | $1.49 | 177,800 |
| 2026-06-01 | $1.48 | 251,900 |
| 2026-05-29 | $1.54 | 188,800 |
| 2026-05-28 | $1.48 | 163,200 |
| 2026-05-27 | $1.41 | 252,100 |
| 2026-05-26 | $1.43 | 233,300 |
| 2026-05-22 | $1.42 | 276,700 |
| 2026-05-21 | $1.45 | 422,700 |
| 2026-05-20 | $1.59 | 334,200 |
| 2026-05-19 | $1.59 | 1,002,300 |
About CEL-SCI Corporation
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
đ° Latest News
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month
Stocktwits âĸ 2026-06-15T11:12:07Z
Cel-Sci: Fiscal Q1 Earnings Snapshot
Associated Press Finance âĸ 2026-02-17T22:14:08ZCel-Sci: Fiscal Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-08-14T13:37:22Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $648,944 | $745,673 | $675,416 | $1,081,034 |
| Total Expenses | $24,809,736 | $26,352,474 | $31,476,074 | $36,062,793 |
| Other Income Expense | $47,625 | $177,682 | $-42,813 | $443,146 |
| Other Non Operating Income Expenses | $47,625 | $177,682 | $-42,813 | $76,355 |
| Net Non Operating Interest Income Expense | $-648,944 | $-745,673 | $-675,416 | $-1,081,034 |
| Interest Expense Non Operating | $648,944 | $745,673 | $675,416 | $1,081,034 |
| Operating Expense | $24,809,736 | $26,352,474 | $31,476,074 | $36,062,793 |
| General And Administrative Expense | $8,922,759 | $8,191,023 | $9,004,578 | $10,707,447 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-25,411,055 | $-26,920,465 | $-32,194,303 | $-36,700,681 |
| Net Interest Income | $-648,944 | $-745,673 | $-675,416 | $-1,081,034 |
| Normalized Income | $-25,411,055 | $-26,920,465 | $-32,194,303 | $-37,067,472 |
| Net Income From Continuing And Discontinued Operation | $-25,411,055 | $-26,920,465 | $-32,194,303 | $-36,700,681 |
| Total Operating Income As Reported | $-24,809,736 | $-26,352,474 | $-31,476,074 | $-36,062,793 |
| Net Income Common Stockholders | $-25,411,055 | $-27,579,921 | $-32,365,855 | $-37,629,803 |
| Net Income | $-25,411,055 | $-26,920,465 | $-32,194,303 | $-36,700,681 |
| Net Income Including Noncontrolling Interests | $-25,411,055 | $-26,920,465 | $-32,194,303 | $-36,700,681 |
| Net Income Continuous Operations | $-25,411,055 | $-26,920,465 | $-32,194,303 | $-36,700,681 |
| Pretax Income | $-25,411,055 | $-26,920,465 | $-32,194,303 | $-36,700,681 |
| Operating Income | $-24,809,736 | $-26,352,474 | $-31,476,074 | $-36,062,793 |
| Average Dilution Earnings | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-6.27 | $-15.31 | $-21.90 | $-26.10 |
| Basic EPS | $-6.27 | $-15.31 | $-21.90 | $-26.10 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-20,876,958 | $-22,205,609 | $-27,560,553 | $-32,157,521 |
| Reconciled Depreciation | $3,885,153 | $3,969,183 | $3,958,334 | $3,828,917 |
| EBITDA (Bullshit earnings) | $-20,876,958 | $-22,205,609 | $-27,560,553 | $-31,790,730 |
| EBIT | $-24,762,111 | $-26,174,792 | $-31,518,887 | $-35,619,647 |
| Diluted Average Shares | $4,055,738 | $1,801,500 | $1,482,662 | $1,438,296 |
| Basic Average Shares | $4,055,738 | $1,801,500 | $1,482,662 | $1,438,296 |
| Diluted NI Availto Com Stockholders | $-25,411,055 | $-27,579,921 | $-32,365,855 | $-37,629,803 |
| Otherunder Preferred Stock Dividend | $0 | $659,456 | $171,552 | $929,122 |
| Research And Development | $15,886,977 | $18,161,451 | $22,471,496 | $25,355,346 |
| Selling General And Administration | $8,922,759 | $8,191,023 | $9,004,578 | $10,707,447 |
| Other Gand A | $8,922,759 | $8,191,023 | $9,004,578 | $10,707,447 |
| Total Unusual Items | - | - | - | $366,791 |
| Total Unusual Items Excluding Goodwill | - | - | - | $366,791 |
| Gain On Sale Of Security | - | - | - | $366,791 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $15,837,229 | $12,701,591 | $13,017,186 | $31,951,006 |
| Total Assets | $28,155,748 | $26,991,766 | $30,528,250 | $50,523,706 |
| Total Non Current Assets | $16,559,620 | $20,936,088 | $23,609,830 | $25,087,790 |
| Other Non Current Assets | $1,218,402 | $1,475,441 | $74,669 | $164,299 |
| Non Current Prepaid Assets | $2,319,101 | $2,319,101 | $2,319,101 | $0 |
| Goodwill And Other Intangible Assets | $119,856 | $165,492 | $197,704 | $212,201 |
| Other Intangible Assets | $119,856 | $165,492 | $197,704 | $212,201 |
| Current Assets | $11,596,128 | $6,055,678 | $6,918,420 | $25,435,916 |
| Prepaid Assets | $339,386 | $297,597 | $524,613 | $762,063 |
| Inventory | $303,282 | $1,019,908 | $2,248,072 | $2,001,715 |
| Cash Cash Equivalents And Short Term Investments | $10,953,460 | $4,738,173 | $4,145,735 | $22,672,138 |
| Cash And Cash Equivalents | $10,953,460 | $4,738,173 | $4,145,735 | $22,672,138 |
| Receivables | - | - | - | $0 |
| Accounts Receivable | - | - | - | $0 |
| Debt | ||||
| Total Debt | $9,383,904 | $11,621,868 | $13,571,749 | $15,303,229 |
| Long Term Debt And Capital Lease Obligation | $6,943,117 | $9,383,904 | $11,602,514 | $13,571,748 |
| Current Debt And Capital Lease Obligation | $2,440,787 | $2,237,964 | $1,969,235 | $1,731,481 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $12,198,663 | $14,124,683 | $17,313,360 | $18,360,499 |
| Total Non Current Liabilities Net Minority Interest | $7,068,117 | $9,508,904 | $11,727,514 | $13,696,748 |
| Other Non Current Liabilities | $125,000 | $125,000 | $125,000 | $125,000 |
| Current Liabilities | $5,130,546 | $4,615,779 | $5,585,846 | $4,663,751 |
| Payables And Accrued Expenses | $2,689,759 | $2,377,815 | $3,616,611 | $2,932,270 |
| Payables | $1,977,939 | $1,811,773 | $2,567,030 | $2,089,778 |
| Other Payable | $916,588 | $363,306 | $557,244 | $471,488 |
| Accounts Payable | $1,061,351 | $1,448,467 | $2,009,786 | $1,618,290 |
| Derivative Product Liabilities | - | - | - | - |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $15,957,085 | $12,867,083 | $13,214,890 | $32,163,207 |
| Total Equity Gross Minority Interest | $15,957,085 | $12,867,083 | $13,214,890 | $32,163,207 |
| Stockholders Equity | $15,957,085 | $12,867,083 | $13,214,890 | $32,163,207 |
| Retained Earnings | $-539,422,916 | $-514,011,861 | $-487,091,396 | $-454,897,093 |
| Other | ||||
| Ordinary Shares Number | $8,015,701 | $2,126,236 | $1,580,743 | $1,448,277 |
| Share Issued | $8,015,701 | $2,126,236 | $1,580,743 | $1,448,277 |
| Tangible Book Value | $15,837,229 | $12,701,591 | $13,017,186 | $31,951,006 |
| Invested Capital | $15,957,085 | $12,867,083 | $13,214,890 | $32,163,207 |
| Working Capital | $6,465,582 | $1,439,899 | $1,332,574 | $20,772,165 |
| Capital Lease Obligations | $9,383,904 | $11,621,868 | $13,571,749 | $15,303,229 |
| Total Capitalization | $15,957,085 | $12,867,083 | $13,214,890 | $32,163,207 |
| Additional Paid In Capital | $555,299,844 | $526,857,678 | $499,832,063 | $486,625,816 |
| Capital Stock | $80,157 | $21,266 | $474,223 | $434,484 |
| Common Stock | $80,157 | $21,266 | $474,223 | $434,484 |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $6,943,117 | $9,383,904 | $11,602,514 | $13,571,748 |
| Current Capital Lease Obligation | $2,440,787 | $2,237,964 | $1,969,235 | $1,731,481 |
| Current Accrued Expenses | $711,820 | $566,042 | $1,049,581 | $842,492 |
| Net PPE | $12,902,261 | $16,976,054 | $21,018,356 | $24,711,290 |
| Accumulated Depreciation | $-12,059,229 | $-10,067,392 | $-7,944,964 | $-5,849,683 |
| Gross PPE | $24,961,490 | $27,043,446 | $28,963,320 | $30,560,973 |
| Leases | $13,924,724 | $13,924,724 | $13,924,724 | $13,544,394 |
| Other Properties | $10,932,173 | $13,014,129 | $14,939,300 | $16,917,283 |
| Machinery Furniture Equipment | $104,593 | $104,593 | $99,296 | $99,296 |
| Properties | $0 | $0 | $0 | $0 |
| Raw Materials | $303,282 | $1,019,908 | $2,248,072 | $2,001,715 |
| Other Short Term Investments | - | - | - | $0 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-17,157,846 | $-18,919,292 | $-23,220,823 | $-18,901,584 |
| Operating Activities | ||||
| Operating Cash Flow | $-17,119,737 | $-18,811,206 | $-22,848,561 | $-18,240,951 |
| Cash Flow From Continuing Operating Activities | $-17,119,737 | $-18,811,206 | $-22,848,561 | $-18,240,951 |
| Operating Gains Losses | - | - | - | $-367,406 |
| Investing Activities | ||||
| Capital Expenditure | $-38,109 | $-108,086 | $-372,262 | $-660,633 |
| Investing Cash Flow | $-38,109 | $-108,086 | $-372,262 | $5,491,367 |
| Cash Flow From Continuing Investing Activities | $-38,109 | $-108,086 | $-372,262 | $5,491,367 |
| Capital Expenditure Reported | $0 | $-13,211 | $-10,370 | $-22,741 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $28,511,095 | $23,655,620 | $6,552,497 | $0 |
| Financing Cash Flow | $23,373,133 | $19,511,730 | $4,694,420 | $-638,426 |
| Cash Flow From Continuing Financing Activities | $23,373,133 | $19,511,730 | $4,694,420 | $-638,426 |
| Net Other Financing Charges | $-3,126,779 | $-2,370,513 | $-744,913 | $-169,445 |
| Net Common Stock Issuance | $28,511,095 | $23,655,620 | $6,552,497 | $0 |
| Common Stock Issuance | $28,511,095 | $23,655,620 | $6,552,497 | $0 |
| Other | ||||
| Repayment Of Debt | $-2,361,183 | $-2,223,377 | $-1,560,455 | $-1,386,495 |
| Issuance Of Debt | $350,000 | $450,000 | $0 | $786,454 |
| Interest Paid Supplemental Data | $768,466 | $923,807 | $1,062,564 | $1,157,069 |
| End Cash Position | $10,953,460 | $4,738,173 | $4,145,735 | $22,672,138 |
| Beginning Cash Position | $4,738,173 | $4,145,735 | $22,672,138 | $36,060,148 |
| Changes In Cash | $6,215,287 | $592,438 | $-18,526,403 | $-13,388,010 |
| Net Issuance Payments Of Debt | $-2,011,183 | $-1,773,377 | $-1,560,455 | $-600,041 |
| Net Short Term Debt Issuance | $0 | $0 | $0 | - |
| Short Term Debt Payments | $-350,000 | $-450,000 | $0 | - |
| Short Term Debt Issuance | $350,000 | $450,000 | $0 | - |
| Net Long Term Debt Issuance | $-2,011,183 | $-1,773,377 | $-1,560,455 | $-600,041 |
| Long Term Debt Payments | $-2,011,183 | $-1,773,377 | $-1,560,455 | $-1,386,495 |
| Net PPE Purchase And Sale | $-38,109 | $-94,875 | $-361,892 | $-637,892 |
| Purchase Of PPE | $-38,109 | $-94,875 | $-361,892 | $-637,892 |
| Change In Working Capital | $1,158,830 | $-1,212,192 | $-1,777,448 | $2,482,799 |
| Change In Other Working Capital | $-3,585 | $745 | $-2,323,346 | $1,910,917 |
| Change In Payables And Accrued Expense | $231,300 | $-1,113,003 | $550,690 | $563,661 |
| Change In Accrued Expense | $120,728 | $-458,489 | $207,089 | $-16,724 |
| Change In Payable | $110,572 | $-654,514 | $343,601 | $580,385 |
| Change In Account Payable | $-442,710 | $-460,576 | $257,845 | $374,890 |
| Change In Prepaid Assets | $-42,550 | $72,674 | $151,935 | $167,651 |
| Change In Inventory | $973,665 | $-172,608 | $-156,727 | $-159,430 |
| Other Non Cash Items | $345,073 | $4,873 | $15,292 | $109,391 |
| Stock Based Compensation | $2,883,987 | $5,347,395 | $7,149,564 | $12,375,236 |
| Asset Impairment Charge | $18,275 | $0 | $0 | $30,793 |
| Depreciation Amortization Depletion | $3,885,153 | $3,969,183 | $3,958,334 | $3,828,917 |
| Depreciation And Amortization | $3,885,153 | $3,969,183 | $3,958,334 | $3,828,917 |
| Net Income From Continuing Operations | $-25,411,055 | $-26,920,465 | $-32,194,303 | $-36,700,681 |
| Proceeds From Stock Option Exercised | - | $0 | $447,291 | $131,060 |
| Long Term Debt Issuance | - | - | $0 | $786,454 |
| Net Investment Purchase And Sale | - | - | $0 | $6,152,000 |
| Sale Of Investment | - | - | $0 | $6,152,000 |
| Change In Receivables | - | - | - | $54,922 |
| Gain Loss On Investment Securities | - | - | - | $-367,406 |
| Purchase Of Investment | - | - | - | - |
| Change In Other Current Liabilities | - | - | - | - |
Fetched: 2026-06-19